The new phase II LORELEI trial tested whether the PI3K inhibitor taselisib could improve response rates when added to letrozole in the neoadjuvant setting.
Could something as simple as synchronizing medicine refills at the pharmacy help improve survival in patients with breast cancer using endocrine therapy?
Using two validation methods, researchers found that a simple biomarker panel may have strong predictive ability for detecting ovarian cancer.
A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.
A new analysis looked at how dose interruptions or reductions of ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes.
The U.S. Preventive Services Task Force released a new review of the benefits and harms of imaging-based screening for pancreatic cancer.
A combination of durvalumab and tremelimumab was tested on patients with metastatic pancreatic ductal adenocarcinoma.
Researchers looked at data from the Surveillance, Epidemiology, and End Results database to see if there has been any increase in the use of active surveillance or watchful waiting when it comes to low-risk prostate cancer.
The study compared PET/CT tracers over 18F-fluciclovine when it comes to the localization of biochemical recurrence of prostate cancer following radical prostatectomy.
Researchers looked at the characteristics of breast cancer found in patients under 40 years old.